With the advantages of rapid extravasation, quick diffusion in extravascular space, and efficient blood clearance, to date, small molecule inhibitors of PSMA have dominated the development of PSMA-targeting imaging agents, therapies, and/or theranostic agents, particularly for prostate cancer. The gene discussed is FOLH1; the disease is Familial prostate cancer.